>
Switch to:

Grifols Debt-to-Asset

: 0.47 (As of Jun. 2021)
View and export this data going back to 2011. Start your Free Trial

Grifols's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $1,084 Mil. Grifols's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $8,080 Mil. Grifols's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2021 was $19,534 Mil. Grifols's debt to asset for the quarter that ended in Jun. 2021 was 0.47.


Grifols Debt-to-Asset Historical Data

The historical data trend for Grifols's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.55 0.48 0.46 0.45

Grifols Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Debt-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.45 0.45 0.46 0.47

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Grifols Debt-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Grifols's Debt-to-Asset falls into.



Grifols Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Grifols's Debt-to-Asset for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(388.77250608273 + 8019.2554744526) / 18582.452554745
=0.45

Grifols's Debt-to-Asset for the quarter that ended in Jun. 2021 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1083.7554216867 + 8079.6481927711) / 19533.793975904
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (NAS:GRFS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Grifols Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Grifols's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Grifols logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 0
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.

Grifols Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)